Comparing LadRx (OTCMKTS:CYTR) and Inhibrx (NASDAQ:INBX)
Comparing LadRx (OTCMKTS:CYTR) and Inhibrx (NASDAQ:INBX)
LadRx (OTCMKTS:CYTR – Get Rating) and Inhibrx (NASDAQ:INBX – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, profitability, dividends, analyst recommendations and institutional ownership.
LADRX (OTCMKTS: CYTR — 獲得評級) 和抑制性 (納斯達克斯:INBX — 獲得評級) 都是小型股醫療公司, 但哪個是更好的股票?我們將根據兩家企業的風險，估值，收益，盈利能力，股息，分析師建議和機構所有權的實力進行比較。
Analyst Recommendations
分析師推薦
This is a summary of current recommendations and price targets for LadRx and Inhibrx, as provided by MarketBeat.com.
這是當前針對 LADRX 和 Inhibrx 的建議和價格目標的摘要，由 MarketBeat.com 提供。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| LadRx | 0 | 0 | 0 | 0 | N/A |
| Inhibrx | 0 | 0 | 4 | 0 | 3.00 |
| 銷售評級 | 保留評分 | 購買評級 | 強大的買入評級 | 評級分數 | |
| LADRX | 0 | 0 | 0 | 0 | N/A |
| 抑制劑 | 0 | 0 | 4 | 0 | 3.00 |
Inhibrx has a consensus price target of $45.25, indicating a potential upside of 98.38%. Given Inhibrx's higher possible upside, analysts plainly believe Inhibrx is more favorable than LadRx.
抑制的價格目標為 45.25 美元，表明潛在的上行空間為 98.38％。鑑於 Inhibrx 的可能較高的上行空間，分析師清楚地認為 Inhibrx 比 LaDrX 更有利。
Volatility & Risk
波動性和風險
LadRx has a beta of 1.96, indicating that its stock price is 96% more volatile than the S&P 500. Comparatively, Inhibrx has a beta of 2.96, indicating that its stock price is 196% more volatile than the S&P 500.
LADRX 的測試版為 1.96，表明其股票價格的波動性比標普 500 高出 96％。相比之下，Inhibrx 的測試值為 2.96，表明其股票價格的波動性比標普 500 大 196%。
Insider & Institutional Ownership
內幕和機構所有權
0.1% of LadRx shares are held by institutional investors. Comparatively, 72.8% of Inhibrx shares are held by institutional investors. 12.8% of LadRx shares are held by company insiders. Comparatively, 25.8% of Inhibrx shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
0.1％ 的股票由機構投資者持有。相比之下，Inhibrx 股票中有 72.8% 是由機構投資者持有的。12.8% 的股票由公司內部人士持有。相比之下，25.8% 的股份由公司內部人士持有。強大的機構所有權表明，對沖基金、大型資金經理和捐贈基金認為股票有望實現長期增長。
Profitability
盈利
This table compares LadRx and Inhibrx's net margins, return on equity and return on assets.
此表格比較了 LaDRX 和 Inhibrx 的淨利潤率、權益回報率和資產回報率。
| Net Margins | Return on Equity | Return on Assets | |
| LadRx | N/A | -67.61% | -45.39% |
| Inhibrx | -6,625.27% | -1,278.54% | -71.71% |
| 淨利潤 | 權益回報率 | 資產回報率 | |
| LADRX | N/A | -67.61% | -45.39% |
| 抑制劑 | -6,625.27% | -1,278.54% | -71.71% |
Valuation & Earnings
估值及收益
This table compares LadRx and Inhibrx's revenue, earnings per share (EPS) and valuation.
此表格比較了 LaDrX 和 Inhibrx 的收入、每股盈利（EPS）和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| LadRx | N/A | N/A | -$6.70 million | ($0.15) | -0.61 |
| Inhibrx | $2.19 million | 453.80 | -$145.23 million | ($3.62) | -6.30 |
| 總收入 | 價格/銷售比率 | 淨收入 | 每股盈利 | 市盈比率 | |
| LADRX | N/A | N/A | -670 萬美元 | (0.15 美元) | -0.61 |
| 抑制劑 | 二百一十九萬元 | 453.80 | -一億四千五百二十三萬美元 | (三百六十二元) | -6.30 |
LadRx has higher earnings, but lower revenue than Inhibrx. Inhibrx is trading at a lower price-to-earnings ratio than LadRx, indicating that it is currently the more affordable of the two stocks.
LaDrX 具有較高的收益，但收入低於抑制布。Inhibrx 的價格與盈利比率低於 LaDrX，這表明它目前在兩隻股票中價格更便宜。
About LadRx
關於我們
(Get Rating)
(取得評分)
LadRx Corporation, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat patients with cancer. The company's advanced drug conjugate, aldoxorubicin that is in late-stage clinical trials is a version of anti-cancer drug doxorubicin. Its pre-clinical therapeutics comprise linker activated drug releases 7, 8, 9, and 10 targeted against cancer The company was formerly known as CytRx Corporation and changed its name to LadRx Corporation in September 2022. LadRx Corporation was incorporated in 1985 and is headquartered in Los Angeles, California.
LADRX Corporation 是一家生物製藥公司，致力於治療癌症患者的治療藥物的發現和開發。該公司的先進藥物共軛，阿多柔比星是在後期臨床試驗中是抗癌藥物多柔比星的一個版本。其臨床前治療包括鏈接器活性藥物釋放 7、8、9 和 10 針對癌症。該公司以前稱為 CyTRX 公司，並於 2022 年 9 月更名為 LADRX 公司。LADRX 公司成立於 1985 年，總部位於加利福尼亞州洛杉磯。
About Inhibrx
關於抑制劑
(Get Rating)
(取得評分)
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.
Inhibrx, Inc. 是一家臨床階段的生物技術公司，致力於開發一系列新穎的生物治療候選人。該公司的治療候選人包括 INBRX-109，死亡受體 5 的四價激動劑，該試驗處於治療癌症的 2 期臨床試驗中，例如軟骨肉瘤，間皮瘤和胰腺癌；INBRX-105 是一種程序性死亡配偶 1 的四價條件激動劑和 4-1BB 的條件激動劑，在局部進行 1 階段臨床轉移試驗的患者腫瘤; 和 INBRX-101，α-1 抗胰蛋白酶（AAT）-Fc 融合蛋白治療候選人，這是在 1 期臨床試驗中使用治療 AAT 缺乏症患者。它還提供 INBRX-106，一種 OX40 的六價激動劑，用於一系列腫瘤適應症。該公司成立於 2010 年，總部位於加利福尼亞州拉霍亞。
Receive News & Ratings for LadRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LadRx and related companies with MarketBeat.com's FREE daily email newsletter.
接收有關 LaDrX 每日的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收對 LADRX 及相關公司的最新新聞和分析師評級的簡要每日摘要。
譯文內容由第三人軟體翻譯。